Dashboard
Manage Tickers

AMGN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sp-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-whats-driving-markets-wednesday
S&P 500, Nasdaq 100 Climb To Record Highs ...
07/03/2024 17:04:01

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...

what-the-options-market-tells-us-about-amgen
What the Options Market Tells Us About Amgen
07/02/2024 20:01:45

amgen-unusual-options-activity
Amgen Unusual Options Activity
07/01/2024 19:02:09

argus-research-maintains-buy-on-amgen-raises-price-target-to-340
Argus Research Maintains Buy on Amgen, Rai...
06/27/2024 17:47:35

Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.

smart-money-is-betting-big-in-amgn-options
Smart Money Is Betting Big In AMGN Options
06/25/2024 16:16:30

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/24/2024 17:35:23

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

check-out-what-whales-are-doing-with-amgn
Check Out What Whales Are Doing With AMGN
06/18/2024 18:46:10

amgen-announces-fda-approval-of-blincyto-in-cd19-positive-philadelphia-chromosome-negative-b-all
Amgen Announces FDA Approval Of BLINCYTO I...
06/14/2024 20:22:51

expert-ratings-for-amgen
Expert Ratings For Amgen
06/14/2024 17:00:24

rbc-capital-maintains-outperform-on-amgen-raises-price-target-to-332
RBC Capital Maintains Outperform on Amgen,...
06/14/2024 13:34:10

RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $328 to $...

decoding-amgens-options-activity-whats-the-big-picture
Decoding Amgen's Options Activity: What's ...
06/12/2024 20:02:22

market-whales-and-their-recent-bets-on-amgn-options
Market Whales and Their Recent Bets on AMG...
06/06/2024 17:46:31

amgen-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference-at-920-am-et-on-june-10
Amgen To Present At Goldman Sachs 45th Ann...
06/05/2024 20:01:09

amgen-seeks-expanded-us-approval-for-autoimmune-disease-drug-acquired-via-28b-horizon-deal
Amgen Seeks Expanded US Approval For Autoi...
06/05/2024 19:26:54

Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key s...

amgen-announces-phase-3-trial-results-for-uplizna-showing-87-reduction-in-igg4-rd-flares-first-randomized-placebo-controlled-trial-to-demonstrate-benefit-in-igg4-rd-all-primary-and-key-secondary-endpoints-met
Amgen Announces Phase 3 Trial Results For ...
06/05/2024 13:01:23

heres-how-much-you-would-have-made-owning-amgen-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
05/31/2024 18:00:45

amgen-secures-fda-nod-for-rare-disease-treatment-biosimilar-based-on-astrazenecas-drug
Amgen Secures FDA Nod For Rare-Disease Tre...
05/29/2024 16:51:29

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare d...

whats-going-on-with-mid-cap-cancer-focused-verastem-oncology-stock-on-friday
What's Going On With Mid-Cap Cancer-Focuse...
05/24/2024 12:45:21

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in ...

exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-ozempic
EXCLUSIVE: Roundhill Investments Launches ...
05/21/2024 20:33:05

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and c...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)